EVALUASI

EKONOMI

-SYSTEMATIC
REVIEW-

NUR FATIMAH
IRENE TENRIANA KENIA
 TOPIC & STRATEGY
Topic :

“Analysis Cost Effectiveness of treatment to Diabetic type 2 for Metformin”

P (Patient/Population) Adult with diabetic type 2, start age 20

– 79, Gender Female
I ( Intervention) Metformin 500 mg

C (Comparative) Dapagliflozin

O (Outcomes) ICER perQALY

Search Literature : Electronic Source – Data base, Electronic Libraries, and Internet
 KRITERIA KELAYAKAN

Menetapkan kritera inklusi dan eksklusi berdasarkan PICOS

Inclution Exclution
Source Pubmed Other source
Dates December 2016 – July 2017
Language English Other language
Population Adult with diabetes type 2 Other population
Intervention Metformin Other Intervention
Comparative Dapagliflozin Other comparator
Outcome ICER and QALY Other outcome
Studies All studies
Type of publication Availability for free journal Paid journal
 KRITERIA KELAYAKAN

Menetapkan kritera inklusi dan eksklusi berdasarkan PICOS

Inclution Exclution
Source Pubmed Other source
Dates December 2016 – July 2017
Language English Other language
Population Adult with diabetes type 2 Other population
Intervention Metformin Other Intervention
Comparative Dapagliflozin Other comparator
Outcome ICER and QALY Other outcome
Studies All studies
Type of publication Availability for free journal Paid journal
 IDENTIFIKASI KATA KUNCI
Menetapkan kritera inklusi dan eksklusi berdasarkan PICOS
Population Intervention Comparative Outcomes

MeSH Term Diabetes type 2 Metformin Dapagliflozin Cost Effectiveness Analysis

Synonim • Diabetes Mellitus, Noninsulin- • (2S,3R,4R,5S,6R)-2-(4-chloro-3- • Analyses, Cost-Benefit

Dependent (4-ethoxybenzyl)phenyl)-6- • Analysis, Cost-Benefit
• Diabetes Mellitus, Ketosis-Resistant (hydroxymethyl)tetrahydro-2H- • Cost-Benefit Analyses
• Ketosis-Resistant Diabetes Mellitus pyran-3,4,5-triol • Cost Benefit Analysis
• Diabetes Mellitus, Non Insulin • Farxiga • Analyses, Cost Benefit
Dependent • Forxiga • Analysis, Cost Benefit
• Non-Insulin-Dependent Diabetes • 2-(3-(4-ethoxybenzyl)-4- • Cost Benefit Analyses
Mellitus chlorophenyl)-6- • Cost Effectiveness
• Diabetes Mellitus, Stable hydroxymethyltetrahydro-2H- • Effectiveness, Cost
• Stable Diabetes Mellitus pyran-3,4,5-triol • Cost-Benefit Data
• Diabetes Mellitus, Type II • BMS 512148 • Cost Benefit Data
• NIDDM • BMS512148 • Data, Cost-Benefit
• Diabetes Mellitus, Noninsulin • BMS-512148 • Cost-Utility Analysis
Dependent • Analyses, Cost-Utility
• Diabetes Mellitus, Maturity-Onset • Analysis, Cost-Utility
• Maturity-Onset Diabetes Mellitus • Cost Utility Analysis
• MODY • Cost-Utility Analyses
• Diabetes Mellitus, Slow-Onset • Economic Evaluation
• Slow-Onset Diabetes Mellitus • Economic Evaluations
• Type 2 Diabetes Mellitus • Evaluation, Economic
• Noninsulin-Dependent Diabetes • Evaluations, Economic
Mellitus • Marginal Analysis
• Maturity-Onset Diabetes • Analyses, Marginal
• Diabetes, Maturity-Onset • Analysis, Marginal
• Maturity Onset Diabetes • Marginal Analyses
• Type 2 Diabetes • Cost Benefit
• Diabetes, Type 2 • Costs and Benefits
HASIL PENCARIAN MESH
 SEARCH LITERATURE/STRATEGY

Dapagliflozin AND Metmorfin

 Characteristic of included studies
Study Location Design Study Period Inclusion Criteria Exclusion Age of Gender Compator Outcome
Criteria Enrollment

Greece

Xiaoling Cai, Chinese 2017 20 – 79 years Female Dapaglifozin

Lizheng Shi dkk